Evaluation of intrapleural fibrinolytic therapy and dosing strategies used for complicated pleural effusions. (October 2022)
- Record Type:
- Journal Article
- Title:
- Evaluation of intrapleural fibrinolytic therapy and dosing strategies used for complicated pleural effusions. (October 2022)
- Main Title:
- Evaluation of intrapleural fibrinolytic therapy and dosing strategies used for complicated pleural effusions
- Authors:
- Baumgartner, Laura
Huang, Eric
Sherman, Deborah - Abstract:
- Abstract: Objectives: Compare the use of Tissue Plasminogen Activator (t-PA) and t-PA + Dornase (DNase) for the management of complicated pleural effusions, and to determine if a dose-response relationship exists for t-PA. Methods: Retrospective cohort study that examined all adult patients at a large academic medical center who received intrapleural t-PA or t-PA + DNase for the management of a complicated pleural effusions. Outcomes were success of therapy [defined as avoidance of secondary interventions (i.e. VATSD or thoracotomy)], chest tube output pre- and post-administration, radiographic findings, t-PA dose and frequency, and bleeding complications. Results: Thirty-five patients were enrolled: 25 received t-PA and 10 received t-PA + DNase. Successful pharmacologic treatment occurred in 88% of patients receiving t-PA and 100% of patients receiving t-PA + DNase (p = 0.54). In the t-PA group, chest tube output increased from 75 ml/12 h to 538 ml/12 h after administration of t-PA (p = 0.001), and from 103 ml/12 h to 502 ml/12 h (p = 0.001) in the t-PA + DNase group. Radiographic improvement occurred in 84% of t-PA patients and 90% of t-PA + DNase patients (p = 0.99). In the t-PA group, a successful response occurred in 92% of patients receiving a cumulative dose of ≤10 mg (n = 13) and 83% of patients receiving a cumulative dose of >10 mg (n = 12), p = 0.43. Patients who received a single t-PA dose compared to those who received multiple doses also had similar successAbstract: Objectives: Compare the use of Tissue Plasminogen Activator (t-PA) and t-PA + Dornase (DNase) for the management of complicated pleural effusions, and to determine if a dose-response relationship exists for t-PA. Methods: Retrospective cohort study that examined all adult patients at a large academic medical center who received intrapleural t-PA or t-PA + DNase for the management of a complicated pleural effusions. Outcomes were success of therapy [defined as avoidance of secondary interventions (i.e. VATSD or thoracotomy)], chest tube output pre- and post-administration, radiographic findings, t-PA dose and frequency, and bleeding complications. Results: Thirty-five patients were enrolled: 25 received t-PA and 10 received t-PA + DNase. Successful pharmacologic treatment occurred in 88% of patients receiving t-PA and 100% of patients receiving t-PA + DNase (p = 0.54). In the t-PA group, chest tube output increased from 75 ml/12 h to 538 ml/12 h after administration of t-PA (p = 0.001), and from 103 ml/12 h to 502 ml/12 h (p = 0.001) in the t-PA + DNase group. Radiographic improvement occurred in 84% of t-PA patients and 90% of t-PA + DNase patients (p = 0.99). In the t-PA group, a successful response occurred in 92% of patients receiving a cumulative dose of ≤10 mg (n = 13) and 83% of patients receiving a cumulative dose of >10 mg (n = 12), p = 0.43. Patients who received a single t-PA dose compared to those who received multiple doses also had similar success rates (p = 1). There was one instance of bleeding following drug administration. Conclusion: Both t-PA and t-PA + DNase were highly effective for reducing a patient's need for surgical intervention. Higher cumulative doses or more frequency administrations did not appear to provide additional benefit. … (more)
- Is Part Of:
- Pulmonary pharmacology & therapeutics. Volume 76(2022)
- Journal:
- Pulmonary pharmacology & therapeutics
- Issue:
- Volume 76(2022)
- Issue Display:
- Volume 76, Issue 2022 (2022)
- Year:
- 2022
- Volume:
- 76
- Issue:
- 2022
- Issue Sort Value:
- 2022-0076-2022-0000
- Page Start:
- Page End:
- Publication Date:
- 2022-10
- Subjects:
- Respiratory organs -- Diseases -- Chemotherapy -- Periodicals
615.7205 - Journal URLs:
- http://www.sciencedirect.com/science/journal/10945539 ↗
http://www.elsevier.com/journals ↗
http://www.journals.elsevier.com/pulmonary-pharmacology-and-therapeutics/ ↗ - DOI:
- 10.1016/j.pupt.2022.102146 ↗
- Languages:
- English
- ISSNs:
- 1094-5539
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 7156.978500
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 23316.xml